AbbVie (NYSE: ABBV), a North Chicago, IL-based company developing medicines and solutions that solve serious health issues, announced the acquisition of Celsius Therapeutics, Inc., a Cambridge, MA-based privately held biotechnology company providing new therapies for patients with inflammatory disease.
Under the terms of the agreement, AbbVie has acquired all outstanding Celsius equity for $250M in cash, subject to certain customary adjustments.
Led by Tariq Kassum, M.D., chief executive officer, Celsius Therapeutics is a clinical-stage biotechnology company developing novel medicines in inflammatory disease. Its lead therapeutic candidate is CEL383, an investigational antibody directed towards TREM1. In preclinical assays, CEL383 has been shown to inhibit TREM1 signaling, reducing the levels of multiple inflammatory mediators of high clinical relevance in inflammatory conditions. A phase 1 first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study evaluating the safety, tolerability and pharmacokinetics of CEL383 in healthy volunteers has concluded.
TREM1 has been identified as a key disease driver gene in IBD, where it is expressed on inflammatory monocytes and neutrophils. In these cell types and others, TREM1 is upstream of multiple known inflammatory pathways and acts as an amplifier of inflammation.
FinSMEs
28/06/2024